Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of the Department of Anaesthesiology of LMU Munich.
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of the Department of Anaesthesiology of LMU Munich. Adult ECMO patients are included in the study after informed consent.
Bleeding and thromboembolic complications as well as treatment details are recorded. Additional coagulation laboratory markers (such as von-Willebrand-factor, ADAMTS13-protease, platelet function tests and thromboelastometric tests) are correlated with clinical signs of bleeding. Regular ultrasound examination of the large vessels are performed to Screen for thrombosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ECMO patients | ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| platelet function parameter | platelet function test | after starting ECMO therapy - up to 28 days after starting ECMO therapy |
| platelet function parameter | platelet function test | one week after ending ECMO therapy |
| coagulation parameter | thromboelastometric test | after starting ECMO therapy - up to 28 days after starting ECMO therapy |
| coagulation parameter | thromboelastometric test | one week after ending ECMO therapy |
| Measure | Description | Time Frame |
|---|---|---|
| inflammatory parameter | bradykinin levels | after starting ECMO therapy - up to 28 days after starting ECMO therapy |
| inflammatory parameter | bradykinin levels |
| Measure | Description | Time Frame |
|---|---|---|
| bleeding assessment | all patients are screened for signs of bleeding or thrombosis | after starting ECMO therapy - up to 28 days after starting ECMO therapy |
| bleeding assessment | all patients are screened for signs of bleeding or thrombosis |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
critically ill patients treated with ECMO
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Zoller, MD | Department of Anaesthesiology, LMU Munich | Principal Investigator |
| Mathias Bruegel, MD | Institute of Laboratory Medicine, LMU Munich | Principal Investigator |
| Dominik J Hoechter, MD | Department of Anaesthesiology, LMU Munich | Study Director |
| Michael Weigand, MD | Institute of Laboratory Medicine, LMU Munich | Study Director |
| Bernhard Zwißler, MD, Prof. | Department of Anaesthesiology, LMU Munich | Study Chair |
| Daniel Teupser, MD, Prof. | Institute of Laboratory Medicine, LMU Munich | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology, LMU Munich | Munich | 81377 | Germany |
sharing individual participant data is restricted by EU General Data Protection Regulation (GDPR)
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D006474 | Hemorrhagic Disorders |
| ID | Term |
|---|---|
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006402 | Hematologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| one week after ending ECMO therapy |
| one week after ending ECMO therapy |
| D006425 |
| Hemic and Lymphatic Diseases |